Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Data submitted by Theravance/Astellas in response to an October FDA “approvable” letter for the antibiotic could be behind the agency’s decision.

You may also be interested in...



Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track

FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.

Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track

FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.

FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date

Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.

Related Content

Topics

UsernamePublicRestriction

Register

PS067299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel